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LETTERS TO THE EDITOR
Comments on the Study by Bono et al
In a recent issue of the Journal, Bono et a l1 present a The most intriguing finding of the study, however, is
study on the /^-adrenoceptor density of lymphocytes the decrease in /?2-adrenoceptor number after treatment
obtained from primary hypertensive and normoten- with the ^-selective antagonist bisoprolol. It is gener-
sive subjects. The main conclusions by the authors ally accepted that treatment with an agonist, either full
were that the /?2-adrenoceptor density was elevated or partial, can induce a decrease in the ^-adrenoceptor
in hypertensives as compared to normotensives. The number, whereas antagonists either induce no change
negative correlation between receptor num ber and or a small increase in ¿^-adrenoceptor number.6 In the
plasma epinephrine concentration, present in normo- present study, the authors show that a /^-selective an-
tensives, was lost in hypertensives bu t could be re- tagonist devoid of partial agonistic activity can induce
stored after 1 month of treatment with the /3,-selective a significant decrease in this parameter. Moreover, the
antagonist bisoprolol. Treatment with verapamil or affinity of bisoprolol for /^-adrenoceptors is relatively
enalapril did not induce such a recovery. Although low, which implies that at the peak plasma concentra-
the study seems carefully conducted, we think that tion indicated in the paper (44.5 ng /m L ) only a small
some of the conclusions are not fully covered by the part of the receptors will be occupied by the antagonist,
*  ^  1  « I I I I I i 4 I t  » 1  1
presented data. making a competitive interaction unlikely. Because
In their paper, the authors present the increased lym- these findings can not be explained by the principles
of normal receptor pharmacology, they call for further 
study in order to elucidate the apparently unusual ac-
1.
v J  »
phocyte /32-adrenoceptor number ha hypertensives as a
well acknowledged fact. In a recent review,2 however, 
we presented data from 14 studies in which this issue was ^on bisoprolol 011 lymphocyte /?2-adienoceptors.
addressed. In eight of the 14 studies (204 hypertensives v 
161 normo tensive subjects; variable numbers per study 
from 10 v 10 to 45 v 41) a significantly higher receptor 
number was found in the hypertensive group, In five 
out the 14 studies (146 hypertensive v 124 normotensive 
subjects; again variable participation per study from 8 v 2,
8 to 72 v 67) 110 significant difference was found. In one 
single study only a positive correlation between blood 
pressure and /^-adrenoceptor density was reported. This 
illustrates that still no definite consensus is reached on 
this subject.
By using the hydrophilic radioligand [3H]-CGP12177, 
the authors claim to measure the cell surface receptors 
that are able to activate adenylyl cyclase. This statement 
is, in our opinion, not valid, Not the amount of ¿02- 
adrenoceptors present on the cell surface but the frac­
tion of receptors able to interact with G-proteins is a 
determinant of receptor activity. According to the 
model of Lefkowitz/1 only receptors that show a high 
affinity agonist binding profile are able to participate 
in signal transduction. We have determined the fraction 
of /^-adrenoceptors on lymphocytes with high affinity 
for isoprenaline, and found that this was less than 40% 
in both hypertensives and normotensives.4 In another 
report it was shown that this fraction was decreased in 
hypertensives5; together with an increased total recep­
tor number this may render a relatively constant 
amount of active membrane /?2-adrenoceptors in hyper­
tensives and normotensives.
4.
REFERENCES
Bono M , Cases A, Calls J, et al: Effect of antihyperten­
sive treatment on the increased /?2-adrenoceptor den­
sity in patients with essential hypertension, Am J Hyp- 
ertens 1995;8:487-493,
Blankesteijn W M , Graafsma SJ, Van Tits LJH , et al: Ad ­
renoceptors in patients with primary hypertension: 
Correlations with blood pressure and some related 
variables. J Hyper tens 1993;11:995-1002.
Lefkowitz RJ, Caron M G, Michel T, Stadel JM : Mecha­
nisms of hormone-effector coupling: the /3-adronergic 
receptor and adenylate cyclase. Fed I’’roc 1982; 41:2664- 
2670,
Blankesteijn WM, Willems PHGM , Graafsma SJ, et al: 
Forskolin stimulated adenylyl cyclase activity is de­
creased but ^-adrenoceptor characteristics are un­
changed in primary hypertension. J Car diova sc Phar­
macol 1993;22:695-701.
5. Feldman RD, Limbird LB, Nadeau J, et al: Leukocyte ~ 
receptor alterations in hypertensive subjects, J Clin In ­
vest 1984;73:648-653.
6. Goodman Gilman A, Rail TW , Nies AS, Taylor P ( eds ) : 
The Pharmacological Basis of Therapeutics, 8th ed. 
New York, Pergamon Press, 1990.
W. M a tth ijs  B la n k e s te ijn , S ie tze  J. G ra a fsm a ,
a n d  T h e o  T h ik n
From the Department of General Internal Medicine, University
Hospital Nijmegen, 
Nijmegen, The Netherlands.
Address correspondence and reprint requests to Dr. W, Matthijs 
Blankesteijn, Department of Pharmacology, University of Limburg, 
Box 616/ 6200 MD Maastricht, The Netherlands.
© 1996 by I he American fou nui! of Hypertension, Lid, 
Published by Elsevier Science, inc.
0895-7061/96/$i5.00 
PII 30895-7061 (96)00029-5
AjH-JULY 1996-VOL. 9, NO. 7 LETTERS TO THE EDITOR 709
Reply to Blankesteijn et al
Despite the fact th a t m o st of the stud ies repo rted  an 
increased /?2-adrenocep to r density  in  essen tial hyper­
tensive patients, especially  those that m easu red  lym ­
phocyte /?2-adrenocep tors in  in tact cells, this is no t an 
universal finding, as B lankesteijn et al s ta ted  in their 
extensive rev iew .1 H o w ev er, in m ost of th e  stud ies
blocker bisoprolol. However, as we dem onstrated no 
receptor occupancy in vitro by bisoprolol, no upregula- 
tion of /32-adrenoceptor num ber should be expected 
w ith  bisoprolol, as Blankesteijn et al stated in their let­
ter. O ur study  suggests that this decrease is associated 
w ith  a norm alization of /3a-adrenoceptor regulation and
that failed to find d ifferences betw een  hypertensive  prelim inary data from our group indicate that bisopro- 
and norm otensive subjects, /?2-ad renocep to r density  lol treatm ent also restores the decreased /3r response
tended to be h igher in  h y p erten siv e  patien ts. F u rther­
more, some stud ies (b o rd erlin e  h y p e rte n s iv e s ) ,23 
show ed huge differences in  body m ass index betw een function in essential hypertension.
observed in these patients. Therefore, bisoprolol treat­
m ent seems to norm alize the im paired /?2-adrenoceptor
2*
patients and co n tro ls1 (in  fact B lankensteijn et al re 
ported in their p a p e r th a t body  m ass index  accounted 
for 9.2% of the v arian ce  of these recep to rs). The ra- 
dioligand and tem p era tu re  of incubation  selected (all 
the studies m ade w ith  CGP12177 as rad io lig an d  found 
increased /32-ad renocep to r density  in essential h y p er­
tensive pa tien ts1 can  also explain  the  lack of differ­
ences in these stud ies.
We partially agree w ith  Blankesteijn et al that the 3 
active receptors are those that are coupled to a G-pro- 
tein and that this is only a fraction of /32-adrenoceptors. 
However, the use of a hydrophilic ligand allows us to 
selectively measure surface receptors, while lipophilic 4. 
ligands also bind to in ternalized  receptors, w hich are 
inactive. Thus, w e u sed  the expression "active" m ean­
ing "able to couple to a G p ro te in /' It is w ell know n 5* 
that not all surface receptors are coupled to adenylyl 
cyclase, but in our s tu d y  the incubation was carried out 
at 4°C. Under these conditions m ost /32-adrenoceptors 
are in a high affinity s ta te /1 On the o ther hand, a de­
creased /32-adrenoceptor response in vitro 2,3'rv> has been 
reported in hypertensive patients. Thus it can be specu­
lated that the increased surface /^¿-adrenoceptor num ­
ber in essential hypertension  is a secondary phenom e­
non trying to com pensate the decreased /^ -ad renocep­
tor intracellular response.
Finally, we agree that it is difficult to explain the 
normalization of /?2-adrenocep to r density in our pa­
tients during trea tm en t w ith  the highly /^-selective
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